TA
PGNX

Teton Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Teton Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,000
Closed -$62K – 473
2019
Q2 		$62K Hold
10,000
– – 0.01% 461
2019
Q1 		$46K Hold
10,000
– – ﹤0.01% 465
2018
Q4 		$42K Hold
10,000
– – ﹤0.01% 459
2018
Q3 		$63K Hold
10,000
– – 0.01% 466
2018
Q2 		$80K Hold
10,000
– – 0.01% 454
2018
Q1 		$75K Buy
+10,000
New +$66.5K 0.01% 443

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Teton Advisors's PGNX Position: Q3 2019 in Review

Teton Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2019, closing a stake of 10,000 shares — an estimated $62K sold.

Teton Advisors first reported a position in PGNX in Q1 2018 and held it in 6 quarters. The position peaked at $80K in Q2 2018. 135 funds tracked by Wall St. Rank hold PGNX as of Q3 2019.

  • Teton Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2019 after selling out during the quarter.
  • Teton Advisors sold 10,000 Progenics Pharmaceuticals Inc shares in Q3 2019, an estimated $62K.
  • Teton Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2018 and held it in 6 quarters.
  • Teton Advisors's Progenics Pharmaceuticals Inc position peaked at $80K in Q2 2018.
  • 135 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2019.

Based on Teton Advisors's 13F filing for Q3 2019, filed 1 Nov 2019.